Cargando…
ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma
Background: Treatment intervention for central nervous system lymphoma (CNSL) requires pathological diagnosis by surgical biopsy. However, there are some cases in which the risk of surgery is high due to age, comorbidities, localization of lesions, etc. We are developing a CNSL diagnostic method bas...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664634/ http://dx.doi.org/10.1093/noajnl/vdab159.088 |
_version_ | 1784613882903396352 |
---|---|
author | Yuki, Yamagishi Sasaki, Nobuyoshi Matsushita, Yuko Shimizu, Saki Matsumoto, Yoshie Saito, Kuniaki Kobayashi, Keiichi Nakatomi, Hirofumi Shiokawa, Yoshiaki Ichimura, Koichi Nagane, Motoo |
author_facet | Yuki, Yamagishi Sasaki, Nobuyoshi Matsushita, Yuko Shimizu, Saki Matsumoto, Yoshie Saito, Kuniaki Kobayashi, Keiichi Nakatomi, Hirofumi Shiokawa, Yoshiaki Ichimura, Koichi Nagane, Motoo |
author_sort | Yuki, Yamagishi |
collection | PubMed |
description | Background: Treatment intervention for central nervous system lymphoma (CNSL) requires pathological diagnosis by surgical biopsy. However, there are some cases in which the risk of surgery is high due to age, comorbidities, localization of lesions, etc. We are developing a CNSL diagnostic method based on the detection of MYD88 L265P mutation by digital PCR (dPCR) using CSF-DNA, and a high accuracy with a sensitivity of 92.9% and a specificity of 100% has been reported. Here, we report two cases with suspected brain stem CNSL, whose treatment strategy was determined by integrated clinico-laboratory information including neurological presentations, imaging, and the result of liquid biopsy. Result: Case 1. A 63-year-old woman visited our hospital with a complaint of right hemiplegia, which deteriorated in two months. MR images revealed a contrast-enhancing lesion in the left midbrain-ventral pons, suggesting CNSL. Biopsy was not considered because of its location, while dPCR using CSF-DNA showed a cluster of MYD88 mutation signals. Based on these work-ups, she was treated with high-dose methotrexate-based chemotherapy, resulting in a complete response with marked improvement of symptoms. Case 2. An 83-year-old man was referred for a history of diplopia and ataxic gait lasting for a month. MR images revealed an invasive lesion on his right midbrain-dorsal pons. Biopsy was declined due to the location, and liquid biopsy using CSF-DNA was performed to assist the diagnosis. In the first test, the CSF-DNA yield was too insufficient to determine the mutation signal by dPCR. The second dPCR using sufficient amount of CSF-DNA resulted in the Target/Total value of 0.049% which was lower than the threshold, suggesting the absence of MYD88 mutation. The patient underwent radiation therapy accordingly.Conclusions: CSF MYD88 mutation analysis by dPCR may have clinical utility and requires sufficient amount of CSF-DNA for exclusion of noise signals. |
format | Online Article Text |
id | pubmed-8664634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86646342021-12-13 ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma Yuki, Yamagishi Sasaki, Nobuyoshi Matsushita, Yuko Shimizu, Saki Matsumoto, Yoshie Saito, Kuniaki Kobayashi, Keiichi Nakatomi, Hirofumi Shiokawa, Yoshiaki Ichimura, Koichi Nagane, Motoo Neurooncol Adv Supplement Abstracts Background: Treatment intervention for central nervous system lymphoma (CNSL) requires pathological diagnosis by surgical biopsy. However, there are some cases in which the risk of surgery is high due to age, comorbidities, localization of lesions, etc. We are developing a CNSL diagnostic method based on the detection of MYD88 L265P mutation by digital PCR (dPCR) using CSF-DNA, and a high accuracy with a sensitivity of 92.9% and a specificity of 100% has been reported. Here, we report two cases with suspected brain stem CNSL, whose treatment strategy was determined by integrated clinico-laboratory information including neurological presentations, imaging, and the result of liquid biopsy. Result: Case 1. A 63-year-old woman visited our hospital with a complaint of right hemiplegia, which deteriorated in two months. MR images revealed a contrast-enhancing lesion in the left midbrain-ventral pons, suggesting CNSL. Biopsy was not considered because of its location, while dPCR using CSF-DNA showed a cluster of MYD88 mutation signals. Based on these work-ups, she was treated with high-dose methotrexate-based chemotherapy, resulting in a complete response with marked improvement of symptoms. Case 2. An 83-year-old man was referred for a history of diplopia and ataxic gait lasting for a month. MR images revealed an invasive lesion on his right midbrain-dorsal pons. Biopsy was declined due to the location, and liquid biopsy using CSF-DNA was performed to assist the diagnosis. In the first test, the CSF-DNA yield was too insufficient to determine the mutation signal by dPCR. The second dPCR using sufficient amount of CSF-DNA resulted in the Target/Total value of 0.049% which was lower than the threshold, suggesting the absence of MYD88 mutation. The patient underwent radiation therapy accordingly.Conclusions: CSF MYD88 mutation analysis by dPCR may have clinical utility and requires sufficient amount of CSF-DNA for exclusion of noise signals. Oxford University Press 2021-12-06 /pmc/articles/PMC8664634/ http://dx.doi.org/10.1093/noajnl/vdab159.088 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Abstracts Yuki, Yamagishi Sasaki, Nobuyoshi Matsushita, Yuko Shimizu, Saki Matsumoto, Yoshie Saito, Kuniaki Kobayashi, Keiichi Nakatomi, Hirofumi Shiokawa, Yoshiaki Ichimura, Koichi Nagane, Motoo ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma |
title | ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma |
title_full | ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma |
title_fullStr | ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma |
title_full_unstemmed | ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma |
title_short | ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma |
title_sort | ml-7 liquid biopsy for myd88 mutation in cerebrospinal fluid in patients with suspected primary cns lymphoma |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664634/ http://dx.doi.org/10.1093/noajnl/vdab159.088 |
work_keys_str_mv | AT yukiyamagishi ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT sasakinobuyoshi ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT matsushitayuko ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT shimizusaki ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT matsumotoyoshie ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT saitokuniaki ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT kobayashikeiichi ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT nakatomihirofumi ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT shiokawayoshiaki ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT ichimurakoichi ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma AT naganemotoo ml7liquidbiopsyformyd88mutationincerebrospinalfluidinpatientswithsuspectedprimarycnslymphoma |